Hexarelin Protects Newborn Brain From Injury Through Akt/GSK-3β Survival Signaling

The GH secretagogue hexarelin reduced neonatal brain injury and activated Akt/GSK-3β neuroprotective signaling pathways, demonstrating direct neuroprotection independent of GH release for birth-related brain damage.

Brywe, Katarina G et al.·Endocrinology·2005·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-01018Animal StudyPreliminary Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Hexarelin reduced neonatal brain injury in a hypoxia-ischemia model and altered Akt/GSK-3β phosphorylation — activating pro-survival signaling cascades for direct GH-independent neuroprotection in the developing brain.

Key Numbers

How They Did This

animal-study study on ghrp, neuroprotection.

Why This Research Matters

Relevant for ghrp, neuroprotection, receptor-signaling.

The Bigger Picture

Advances peptide research with translational implications.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Hexarelin reduced neonatal brain injury in a hypoxia-ischemia model and altered Akt/GSK-3β phosphorylation — activating pro-survival signaling cascade
Evidence Grade:
preliminary evidence.
Study Age:
Published in 2005.
Original Title:
Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.
Published In:
Endocrinology, 146(11), 4665-72 (2005)
Database ID:
RPEP-01018

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Hexarelin Protects Newborn Brain From Injury Through Akt/GSK-3β Survival Signaling

What was found?

The GH secretagogue hexarelin reduced neonatal brain injury and activated Akt/GSK-3β neuroprotective signaling pathways, demonstrating direct neuroprotection independent of GH release for birth-related brain damage.

Read More on RethinkPeptides

Cite This Study

RPEP-01018·https://rethinkpeptides.com/research/RPEP-01018

APA

Brywe, Katarina G; Leverin, Anna-Lena; Gustavsson, Malin; Mallard, Carina; Granata, Riccarda; Destefanis, Silvia; Volante, Marco; Hagberg, Henrik; Ghigo, Ezio; Isgaard, Jörgen. (2005). Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.. Endocrinology, 146(11), 4665-72.

MLA

Brywe, Katarina G, et al. "Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.." Endocrinology, 2005.

RethinkPeptides

RethinkPeptides Research Database. "Growth hormone-releasing peptide hexarelin reduces neonatal ..." RPEP-01018. Retrieved from https://rethinkpeptides.com/research/brywe-2005-growth-hormonereleasing-peptide-hexarelin

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.